Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under “NHWK” Effective at the Market Open Today
Heat Biologics (“NightHawk Biosciences”) Completes Acquisition of Elusys Therapeutics
Heat Biologics Announces Planned Name Change to NightHawk Biosciences, Reflecting Company's Evolution, Therapeutic Pipeline Expansion, Vertical Integration and New Biodefense Capabilities
REMINDER: Heat Biologics to Host Planned Investor and Media Livestream Event on Tuesday, April 19th at 10:30 AM ET to Discuss Latest Developments
Heat Biologics' Scorpion Subsidiary Announces Planned Development of New Kansas Commercial/Biodefense Biomanufacturing Facility
Heat Biologics' Announces Planned Investor and Media Livestream Event to Discuss Latest Developments
Heat Biologics Unveils Enhanced Allogeneic Cell Manufacturing Process
Heat Biologics Announces Appointment of Greg Burel, Former Director of the Strategic National Stockpile, to its Biothreat Advisory Board and as Senior Advisor to the Company
Heat Biologics Announces Planned Transfer to the NYSE American
Heat Biologics' Merger Partner Elusys Finalizes HHS Contract For Its Anthrax Treatment
Elusys Therapeutics Finalizes HHS Contract to Deliver ANTHIM®, Its Treatment for Inhalation Anthrax, to the U.S. Department of Health and Human Services
Heat Biologics Issues New PTX-35 Preclinical Data In Organ Transplantation, Update On HS-110
Heat Biologics To Bolster Presence In Biodefense Space With Elusys Acquisition
Heat Biologics Announces Planned Acquisition of Elusys Therapeutics
Heat Biologics Unveils RapidVax®, A Novel Cellular Vaccine Platform Targeting Known and Unknown Emerging Biological Threats
Heat Biologics Appoints Paul Tebbey as Senior Vice President of Product Development and Portfolio Strategy
Heat Biologics CEO to Present at the Cantor Fitzgerald Global Healthcare Conference on September 29th
Heat Biologics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Heat Biologics to Provide Corporate Update
Heat Biologics Is Starting To Run Away From Support Toward Resistance
Heat Biologics Unveils Skunkworx Bio, New Drug Discovery Subsidiary
Heat Biologics Announces Addition of Former US Senator Mark Pryor to Biothreat Advisory Board
Heat Biologics Provides Second Quarter 2021 Business Update
Heat Biologics Announces Groundbreaking for New San Antonio Facility
Heat Biologics Joins Russell Microcap® Index
Heat Biologics Announces Significant Expansion of R&D and Pre-Clinical Capabilities at Corporate Headquarters
HTBX Stock Price: 40.15% Increase Explanation
Heat Biologics Surges On Patent Filing
Heat Biologics to Showcase Favorable Survival Data of HS-110 in Previously Treated Non-Small Cell Lung Cancer Patients at 2021 American Society of Clinical Oncology Annual Meeting
Heat Biologics' Lead Candidate Shows Overall Survival Benefit In Lung Cancer Study
Heat Biologics Announces Promising Survival Data of HS-110 in Two Treatment Settings of Lung Cancer; Selected for Presentation at 2021 American Society of Clinical Oncology Annual Meeting
Heat Biologics Announces Multiple Presentations on PTX-35 at the Upcoming 3rd Annual Treg Directed Therapies Summit
Heat Biologics Appoints Anthony Manning, Ph.D. as Chief Scientific Advisor
Heat Biologics Provides First Quarter 2021 Business Update; Reports Continued Progress on Oncology and COVID-19 Vaccine Programs
NSPR Stock: What You Should Know About InspireMD Today
Heat Biologics Announces New Preclinical Data on PTX-35, Demonstrating Decreased Regulatory T-cell (Treg) Activity and Delayed Tumor Progression at American Association for Cancer Research (AACR) Annual Meeting 2021
Heat Biologics Provides Year-End Business Update
Heat Biologics to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
HTBX Stock: Why Shares of Heat Biologics Are Blazing Higher Today
HTBX Stock Price Increases Over 25% Pre-Market: Why It Happened
Heat Biologics Catapults After Drug Regimen Boosts Lung-Cancer Survival
HTBX Stock Price Increased 103.1% In Day High: Why It Happened
Heat Biologics stock more than doubles after 'positive' trial data of its lung cancer treatment
Heat Biologics Cell Therapy Shows Survival Benefit In Mid-Stage Lung Cancer Study, Shares Rally
HTBX Stock Price Increases Over 6% Pre-Market: Why It Happened
Heat Biologics: Investors Would Be Wise To Hold Off Until 2H 2021 Clinical Trial Interim Results
Heat Biologics Commences Manufacturing Process for ZVX-60
Heat Biologics Promotes William L. Ostrander to Chief Financial Officer
Heat Biologics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
Heat Biologics Reverse Stock Split: 10 Things for HTBX Stock Investors to Know